Global R&D Milestone: Clinical Trial of GenSci120 Will Be Launched in the U.S.

Recently, Changchun GeneScience Pharmaceutical Co., Ltd. (GenSci) announced that the PD-1 agonist GenSci120 Injection has received U.S. FDA implied license to initiate clinical trials in the United States for Rheumatoid Arthritis (RA).

GenSci120 is a humanized PD-1 monoclonal antibody independently developed by GenSci. GenSci120 exhibits potential for the treatment of autoimmune diseases and has demonstrated "Best-in-Class" (BIC) potential in preclinical studies.

In the United States, GenSci120 is classified as a Section 351(a) biological product. This implied license not only marks the drug's entry into global clinical trials, but also validates the international promise of PD-1 agonist innovation in autoimmune disease treatment. Since the inception, GenSci has remained steadfast in pursuing an innovation-driven development strategy, committed to building a globally integrated open R&D ecosystem to benefit patients worldwide.